Role of biochemical markers in the management of osteoporosis.
Several serum and urine biochemical markers of bone resorption and formation have been developed. Biochemical bone markers have been used as intermediate end-points in all major studies of anti-osteoporotic therapies. Bone resorption markers, in particular, may add an independent, predictive value to the assessment of bone loss and fracture risk. There are also potential advantages in monitoring anti-osteoporotic treatment in the short-term in addition to bone densitometry, to rapidly identify non-responders to therapy, or non-compliance. Despite these recent advances, until now bone markers have simply been very useful research tools, with their clinical utility being limited by intra-individual and diurnal variability. However, the probability of the true bone mineral density response to hormone replacement therapy for the individual patient may be predicted using algorithms based on a spectrum of cut-off bone marker levels with varying false positive and negative rates. Thus, the transition of biochemical bone markers into everyday clinical practice may be rapidly approaching.
Ebeling
P R
PR
Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, 3050, Australia.
Akesson
K
K
D015415:Biomarkers / Q000032:analysis*; D001862:Bone Resorption / Q000503:physiopathology; D006801:Humans; D010012:Osteogenesis / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy*
D015415:Biomarkers